Artikel: [Efficacy and safety of bacterial lysate OM-85 in the treatment of uncomplicated acute respiratory infections: a double-blind, placebo-controlled, multicenter, randomized trial].
2023 Band 95, Heft 10, Seite(n) 850–858
Abstract: Aim: To evaluate the efficacy and safety of OM-85 in the treatment of uncomplicated acute respiratory infections (ARI) in adults.: Materials and methods: A double-blind, placebo-controlled, multicenter, randomized trial included 556 patients (18-60 ... ...
Abstract | Aim: To evaluate the efficacy and safety of OM-85 in the treatment of uncomplicated acute respiratory infections (ARI) in adults. Materials and methods: A double-blind, placebo-controlled, multicenter, randomized trial included 556 patients (18-60 years old) with mild and moderate ARI and negative results of polymerase chain reaction analysis for SARS-CoV-2 RNA and rapid test for influenza A and B viruses. Patients were randomized into two groups: in the first group ( Results: The superiority of OM-85 over placebo by primary endpoint was observed on the 5th, 7th and 10th days of treatment. OM-85 efficacy has also been proven by secondary criteria. OM-85 shortened the time until the symptoms of ARI resolved according to the WURSS-21 and CCQ, increased the proportion of patients with body temperature below 37°C by 2-9 days. The time needed to resolve the symptoms of disease in 20% of patients according to WURSS-21 was 7 and 9 days in patients taking OM-85 and placebo, respectively. Bacterial lysate increased the probability of complete disappearance of symptoms according to CCQ by 45.7% compared to placebo. The analysis of the frequency and severity of adverse events, laboratory tests, physical and instrumental examination results during treatment confirmed the good tolerability and safety of OM-85. Conclusion: The study confirmed the efficacy and safety of OM-85 in the complex treatment of ARI in adults. |
---|---|
Mesh-Begriff(e) | Adult ; Humans ; Adolescent ; Young Adult ; Middle Aged ; Bacterial Lysates ; RNA, Viral/therapeutic use ; Respiratory Tract Infections/drug therapy ; Influenza, Human/drug therapy ; Common Cold ; Double-Blind Method ; Bacteria ; Treatment Outcome |
Chemische Substanzen | Bacterial Lysates ; RNA, Viral |
Sprache | Russisch |
Erscheinungsdatum | 2023-11-23 |
Erscheinungsland | Russia (Federation) |
Dokumenttyp | Randomized Controlled Trial ; Multicenter Study ; English Abstract ; Journal Article |
ZDB-ID | 40718-5 |
ISSN | 2309-5342 ; 0040-3660 |
ISSN (online) | 2309-5342 |
ISSN | 0040-3660 |
DOI | 10.26442/00403660.2023.10.202464 |
Datenquelle | MEDical Literature Analysis and Retrieval System OnLINE |
Zusatzmaterialien
Kategorien
Verfügbar in ZB MED Köln/Königswinter
Zs.A 79: Hefte anzeigen | Standort: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
Über subito bestellen
Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.